Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

about

Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.Transforming growth factor beta1 and aldosterone.

P2860

Q26996385-1EA8514B-CAD2-4E1C-93C2-AE3BA9950E1B Q38238367-1341EA7A-1815-407C-8A7D-48540684E506 Q38318139-192FF921-D2C7-4AB9-9530-6E74F9158F77

P2860

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

Item

http://www.wikidata.org/entity/Q50925186

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

@en

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

@nl

type

Item

label

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

@en

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

@nl

prefLabel

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

@en

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

@nl

P1476

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1

@en

P2093

Alberto Edefonti

http://www.w3.org/2001/XMLSchema#string

Amedea Silvia Tirelli

http://www.w3.org/2001/XMLSchema#string

Antonio Mastrangelo

http://www.w3.org/2001/XMLSchema#string

Giuseppina Marra

http://www.w3.org/2001/XMLSchema#string

Helmut Hopfer

http://www.w3.org/2001/XMLSchema#string

Marisa Giani

http://www.w3.org/2001/XMLSchema#string

Roberta Villa

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion

Identification of mutations in the COL4A5 collagen gene in Alport syndrome

X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study

Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells

Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.

Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model.

Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy.

Glomerular pathology in Alport syndrome: a molecular perspective.

Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade.

Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative.

P2888

s00467-013-2490-z

P304

1837-1842

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00467-013-2490-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stefano Turolo

P577

2013-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23748277

http://www.w3.org/2001/XMLSchema#string

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

about

P2860

P2860

Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698